Genetically modified immune cells have extraordinary potential to be utilised in various immunotherapies (eg. HIV or refractory diseases, such as relapsed hematological malignancies). Gene delivery into resting immune cells is preferable given their superior capacity for engraftment, differentiation and effector functions. Whilst lentiviral vectors can act as delivery tools for resting cell types, dominant host-restrictions limit their capacity in resting immune cells. This project will be focussed on developing lentiviral platforms for resting immune cells using a system of viral evolution and viral gene bioprospecting. In tackling gene delivery, this project has the potential to transform future immunotherapeutic strategies.
Back to search results
The Kirby Institute